Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to compare the eradication rates of sequential therapy for 10 days versus triple therapy for 14 days

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Amoxicillin; Clarithromycin; Dexlansoprazole; Lansoprazole; Metronidazole

Criteria

Inclusion Criteria:

• Patients are aged greater than 20 years who have H. pylori infection without prior eradication therapy and are willing to receive the sequential therapy will be eligible for enrollment.

• Written informed consents will be obtained from all patients prior to enrollment.

Exclusion Criteria:

Patients will be excluded from the study if any one of the following criteria is present:

• children and teenagers aged less than 20 years,

• history of gastrectomy,

• gastric malignancy, including adenocarcinoma and lymphoma,

• previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin, metronidazole) and prompt pump inhibitors (lansoprazole), - contraindication to treatment drugs,

• pregnant or lactating women,

• severe concurrent disease

• Patients who cannot give informed consent by himself or herself.